ClinicalTrials.gg
CompletedNCT03025542Updated Mar 24, 2026Results posted

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

A Phase 2 interventional study of Bimekizumab and Placebo in Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 8 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
14th of 20
49 · median 161
Started
2016
with 2 others
Phase 2
6 of 20
1 open now
Registered
4th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 14th largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 2, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Chronic Plaque Psoriasis
  • Bimekizumab
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years of age and less than or equal to 70
  • Chronic plaque psoriasis for at least 6 months prior to Screening
  • Psoriasis Area and Severity Index (PASI) >=12 and body surface area (BSA) >=10% and Investigator's Global Assessment (IGA) score >=3 on a 5-point scale
  • Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy
  • Female subjects must be , permanently sterilized or, if of , must be willing to use a highly effective method of up till 20 weeks after last administration of study drug, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 half-lives)

Exclusion criteria

Exclusion Criteria:

  • Subjects previously participating in a bimekizumab study
  • Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis
  • History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline Visit (including herpes zoster)
  • High risk of infection in the Investigator's opinion
  • Current sign or symptom that may indicate an active infection
  • Concurrent acute or chronic viral or C or (HIV) infection
  • Live (includes attenuated) vaccination within the 8 weeks prior to Baseline
  • Subjects with concurrent or history of malignancy during the past 5 years (except for specific malignant condition as defined in the protocol)
  • Primary conditions
  • TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or current or history of NTMB infection
  • Laboratory abnormalities, as defined in the study protocol
  • Any condition which, in the Investigator's judgement, would make the subject unsuitable for inclusion in the study
  • Exposure to more than 1 biological response modifier (limited to anti-TNF or IL-12/-23) or any biologic response modifier during the three months prior to the Baseline Visit
  • Subjects have received previous treatment with any anti-IL-17 therapy for the treatment of psoriasis or psoriatic arthritis
  • Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus. Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease at Screening or Baseline
  • Subjects taking psoriatic arthritis medications other than nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Treatment Arm 1

    Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.

    Drug: Bimekizumab · Other: Placebo

  • Experimental
    Treatment Arm 2

    Subjects randomized in this arm will receive Bimekizumab injections.

    Drug: Bimekizumab

Interventions

  • Based on their randomization subjects will receive a combination of several injections of Bimekizumab.

    Also known as: UCB4940

  • OtherPlacebo

    Subjects will receive injections of Placebo.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28

    The PASI is the most commonly used and validated assessment for grading the severity of psoriasis in clinical studies. The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The percent area of involvement (BSA%) is estimated across 4 body areas; head (10%), upper limbs (20%), trunk (30%), and lower limbs (40%) and then transferred into a grade. The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5 point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.

    Time frame: From Baseline to Week 28

  2. Plasma Concentration of Bimekizumab at Baseline

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Baseline

  3. Plasma Concentration of Bimekizumab at Week 2

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 2

  4. Plasma Concentration of Bimekizumab at Week 4

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 4

  5. Plasma Concentration of Bimekizumab at Week 8

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 8

  6. Plasma Concentration of Bimekizumab at Week 12

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 12

  7. Plasma Concentration of Bimekizumab at Week 16

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (µg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 16

  8. Plasma Concentration of Bimekizumab at Week 20

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 20

  9. Plasma Concentration of Bimekizumab at Week 24

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 24

  10. Plasma Concentration of Bimekizumab at Week 28

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 28

  11. Plasma Concentration of Bimekizumab at Week 36

    Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

    Time frame: at Week 36

  12. Percentage of Participants Reporting Positive Anti-Drug-Antibodies (ADA) Titre Prior to Study Treatment With Bimekizumab at Baseline

    An ADA status of positive was concluded for any participant with an ADA level that was above cut point (ACP) and 'confirmed positive' (CP) at any time point. A participant was classified as having treatment-induced ADA positivity when meeting one of the following criteria: -The Baseline result was either below cut point (BCP) or ACP and 'not confirmed positive' (NCP), and at least 1 post Baseline time point was ACP and CP. -The Baseline result was positive (ACP and CP) and at least one post-Baseline measurement showed a pre-defined fold increase in titre from the Baseline value. Note: The overall status of a participant is 'Positive' if at any post-Baseline visit the result was ACP and confirmed positive.

    Time frame: at Baseline

  13. Percentage of Participants Reporting an Overall Positive Anti-Drug-Antibodies (ADA) Titre Following Study Treatment With Bimekizumab

    An ADA status of positive was concluded for any participant with an ADA level that was above cut point (ACP) and 'confirmed positive' (CP) at any time point. A participant was classified as having treatment-induced ADA positivity when meeting one of the following criteria: -The Baseline result was either below cut point (BCP) or ACP and 'not confirmed positive' (NCP), and at least 1 post Baseline time point was ACP and CP. -The Baseline result was positive (ACP and CP) and at least one post-Baseline measurement showed a pre-defined fold increase in titre from the Baseline value. Note: The overall status of a participant is 'Positive' if at any post-Baseline visit the result was ACP and confirmed positive.

    Time frame: From Baseline to Safety Follow-Up Visit (Week 36)

  14. Percentage of Participants Who Experienced at Least One Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Within the Safety Set, this trial reported a total of 164 occurences of adverse events, of which 7 were pre-treatment adverse events and 157 were treatment-emergent adverse events (TEAEs).

    Time frame: From Screening to Safety Follow-Up Visit (Week 36)

Secondary outcomes

  1. Percentage of Participants Achieving a 75% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16

    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: From Baseline to Week 16

  2. Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16

    The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: From Baseline to Week 16

  3. Percentage of Participants Achieving a 100% Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16

    The PASI100 response assessments are based on at least 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: From Baseline to Week 16

  4. Percentage of Participants With IGA (Investigator´s Global Assessment) Response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

    Time frame: at Week 16

07

Results

Posted Jan 6, 2021

Participant flow

The study started to enroll patients in December 2016 and concluded in December 2017.

Participant flow — Overall Study
MilestoneBimekizumab 320 mg + PBOBimekizumab 320 mg
Started3217
Completed3015
Not completed22
Withdrew: Adverse event02
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryChange From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28

The PASI is the most commonly used and validated assessment for grading the severity of psoriasis in clinical studies. The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The percent area of involvement (BSA%) is estimated across 4 body areas; head (10%), upper limbs (20%), trunk (30%), and lower limbs (40%) and then transferred into a grade. The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5 point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.

Time frame:
From Baseline to Week 28
Reported as:
Mean · scores on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28
scores on a scaleBimekizumab 320 mg + PBO (FAS)Bimekizumab 320 mg (FAS)
Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28-10.76 ± 7.58-19.74 ± 8.77
PrimaryPlasma Concentration of Bimekizumab at Baseline

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Baseline
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Baseline
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at BaselineNA (NA to NA)NA (NA to NA)
PrimaryPlasma Concentration of Bimekizumab at Week 2

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 2
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 2
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 219.749 (17.0 to 23.0)14.437 (10.8 to 19.3)
PrimaryPlasma Concentration of Bimekizumab at Week 4

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 4
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 4
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 411.402 (9.7 to 13.4)9.077 (7.2 to 11.5)
PrimaryPlasma Concentration of Bimekizumab at Week 8

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 8
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 8
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 816.728 (14.4 to 19.5)13.969 (11.1 to 17.6)
PrimaryPlasma Concentration of Bimekizumab at Week 12

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 12
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 12
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 125.972 (4.9 to 7.3)5.466 (3.9 to 7.7)
PrimaryPlasma Concentration of Bimekizumab at Week 16

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (µg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 16
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 16
µg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 162.200 (1.6 to 3.0)2.293 (1.4 to 3.7)
PrimaryPlasma Concentration of Bimekizumab at Week 20

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 20
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 20
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 200.798 (0.5 to 1.2)9.702 (7.3 to 13.0)
PrimaryPlasma Concentration of Bimekizumab at Week 24

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 24
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 24
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 24NA (NA to NA)4.377 (3.2 to 6.0)
PrimaryPlasma Concentration of Bimekizumab at Week 28

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 28
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 28
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 28NA (NA to NA)1.933 (1.2 to 3.1)
PrimaryPlasma Concentration of Bimekizumab at Week 36

Plasma concentration was expressed as geometric mean concentrations (GMCs) and measured in micrograms per milliliter (μg/mL). Note: Means, Lower confidence interval (LCI), Upper confidence interval (UCI) are only calculated if at least 2/3 of the concentrations were quantified at the respective time point. Values below limit of quantification (BLQ) are replaced by value of lower limit of quantification (LLOQ)/2 (=0.075ug/mL) in calculations of means.

Time frame:
at Week 36
Reported as:
Geometric mean · μg/mL
Plasma Concentration of Bimekizumab at Week 36
μg/mLBimekizumab 320 mg + PBO (PK-PPS)Bimekizumab 320 mg (PK-PPS)
Plasma Concentration of Bimekizumab at Week 36NA (NA to NA)0.322 (0.2 to 0.6)
PrimaryPercentage of Participants Reporting Positive Anti-Drug-Antibodies (ADA) Titre Prior to Study Treatment With Bimekizumab at Baseline

An ADA status of positive was concluded for any participant with an ADA level that was above cut point (ACP) and 'confirmed positive' (CP) at any time point. A participant was classified as having treatment-induced ADA positivity when meeting one of the following criteria: -The Baseline result was either below cut point (BCP) or ACP and 'not confirmed positive' (NCP), and at least 1 post Baseline time point was ACP and CP. -The Baseline result was positive (ACP and CP) and at least one post-Baseline measurement showed a pre-defined fold increase in titre from the Baseline value. Note: The overall status of a participant is 'Positive' if at any post-Baseline visit the result was ACP and confirmed positive.

Time frame:
at Baseline
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Positive Anti-Drug-Antibodies (ADA) Titre Prior to Study Treatment With Bimekizumab at Baseline
percentage of participantsBimekizumab 320 mg + PBO (SS)Bimekizumab 320 mg (SS)
Percentage of Participants Reporting Positive Anti-Drug-Antibodies (ADA) Titre Prior to Study Treatment With Bimekizumab at Baseline3.10
PrimaryPercentage of Participants Reporting an Overall Positive Anti-Drug-Antibodies (ADA) Titre Following Study Treatment With Bimekizumab

An ADA status of positive was concluded for any participant with an ADA level that was above cut point (ACP) and 'confirmed positive' (CP) at any time point. A participant was classified as having treatment-induced ADA positivity when meeting one of the following criteria: -The Baseline result was either below cut point (BCP) or ACP and 'not confirmed positive' (NCP), and at least 1 post Baseline time point was ACP and CP. -The Baseline result was positive (ACP and CP) and at least one post-Baseline measurement showed a pre-defined fold increase in titre from the Baseline value. Note: The overall status of a participant is 'Positive' if at any post-Baseline visit the result was ACP and confirmed positive.

Time frame:
From Baseline to Safety Follow-Up Visit (Week 36)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting an Overall Positive Anti-Drug-Antibodies (ADA) Titre Following Study Treatment With Bimekizumab
percentage of participantsBimekizumab 320 mg + PBO (SS)Bimekizumab 320 mg (SS)
Percentage of Participants Reporting an Overall Positive Anti-Drug-Antibodies (ADA) Titre Following Study Treatment With Bimekizumab34.447.1
PrimaryPercentage of Participants Who Experienced at Least One Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Within the Safety Set, this trial reported a total of 164 occurences of adverse events, of which 7 were pre-treatment adverse events and 157 were treatment-emergent adverse events (TEAEs).

Time frame:
From Screening to Safety Follow-Up Visit (Week 36)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least One Adverse Events (AEs)
percentage of participantsBimekizumab 320 mg + PBO (SS)Bimekizumab 320 mg (SS)
Percentage of Participants Who Experienced at Least One Adverse Events (AEs)87.588.2
SecondaryPercentage of Participants Achieving a 75% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16

The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
From Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 75% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16
percentage of participantsBimekizumab 320 mg + PBO (FAS)Bimekizumab 320 mg (FAS)
Percentage of Participants Achieving a 75% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 1693.888.2
SecondaryPercentage of Participants Achieving a 90% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
From Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16
percentage of participantsBimekizumab 320 mg + PBO (FAS)Bimekizumab 320 mg (FAS)
Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 1684.470.6
SecondaryPercentage of Participants Achieving a 100% Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16

The PASI100 response assessments are based on at least 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Time frame:
From Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 100% Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 16
percentage of participantsBimekizumab 320 mg + PBO (FAS)Bimekizumab 320 mg (FAS)
Percentage of Participants Achieving a 100% Improvement From Baseline in PASI (Psoriasis Area and Severity Index) Score at Week 1646.952.9
SecondaryPercentage of Participants With IGA (Investigator´s Global Assessment) Response at Week 16

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.

Time frame:
at Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With IGA (Investigator´s Global Assessment) Response at Week 16
percentage of participantsBimekizumab 320 mg + PBO (FAS)Bimekizumab 320 mg (FAS)
Percentage of Participants With IGA (Investigator´s Global Assessment) Response at Week 1681.364.7

Adverse events

Collected over From Baseline to Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab 320 mg + PBO (SS)0/32 (0%)2/32 (6.3%)28/32 (87.5%)
Bimekizumab 320 mg (SS)0/17 (0%)1/17 (5.9%)15/17 (88.2%)
Most frequent serious events
Most frequent serious events
EventBimekizumab 320 mg + PBO (SS)Bimekizumab 320 mg (SS)
PancreatitisGastrointestinal disorders0/321/17
Cholecystitis acuteHepatobiliary disorders0/321/17
SyncopeNervous system disorders1/320/17
Peripheral sensorimotor neuropathyNervous system disorders1/320/17
Most frequent other events
Showing 10 of 42
Most frequent other events
EventBimekizumab 320 mg + PBO (SS)Bimekizumab 320 mg (SS)
NasopharyngitisInfections and infestations2/324/17
Upper respiratory tract infectionInfections and infestations6/323/17
Alanine aminotransferase increasedInvestigations2/323/17
Gamma-glutamyltransferase increasedInvestigations2/323/17
White blood cell count decreasedMetabolism and nutrition disorders2/323/17
Neutrophil count decreasedInvestigations1/323/17
Urinary tract infectionInfections and infestations4/320/17
HyperkalaemiaMetabolism and nutrition disorders4/321/17
Viral upper respiratory tract infectionInfections and infestations2/322/17
Viral infectionInfections and infestations0/322/17

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS) which consisted of all participants who received at least 1 dose of the study medication.

Age, Categorical
Age, Categorical(Participants)Bimekizumab 320 mg + PBOBimekizumab 320 mgTotal Title
<=18 years000
Between 18 and 65 years301646
>=65 years213
Age, Continuous
Age, Continuous(years)Bimekizumab 320 mg + PBOBimekizumab 320 mgTotal Title
Mean41.8 ± 14.145.9 ± 10.443.2 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab 320 mg + PBOBimekizumab 320 mgTotal Title
Female17623
Male151126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab 320 mg + PBOBimekizumab 320 mgTotal Title
Asian145
Black or African American101
Native Hawaiian or Other Pacific Islander011
White301242
08

Study locations

8 sites
  • Ps0016 704
    Bexley, Ohio, United States
  • Ps0016 102
    Kogarah, Australia
  • Ps0016 101
    Melbourne, Australia
  • Ps0016 104
    Woolloongabba, Australia
  • Ps0016 201
    Ajax, Canada
  • Ps0016 203
    London, Canada
  • Ps0016 202
    Windsor, Canada
  • Ps0016 501
    Chisinau, Moldova
09

References and documents

Publications

  • Oliver R, Krueger JG, Glatt S, Vajjah P, Mistry C, Page M, Edwards H, Garcet S, Li X, Dizier B, Maroof A, Watling M, El Baghdady A, Baeten D, Ionescu L, Shaw S. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27. PubMed 34687214 ↗
  • Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PubMed 35544084 ↗
  • Krueger JG, Cutcutache I, Lebwohl M, Gudjonsson JE, Pinter A, Langley RG, Merola J, Tada Y, Skelton A, Rastrick J, Ferecsko AS, Page M, Davies O, Lopez Pinto JM, Warham R, Shaw S, Warren RB. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability. J Allergy Clin Immunol. 2026 Apr;157(4):905-916. doi: 10.1016/j.jaci.2025.12.1013. Epub 2026 Jan 22. PubMed 41580158 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Dec 2017, 11 months.

Results were first posted in Jan 2021, 3 years after primary completion. A results delay was requested in Dec 2018.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 11 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Jan 19, 2017
StartActual
Dec 27, 2016
Primary completionActual
Dec 11, 2017
CompletionActual
Dec 11, 2017
Results delay requested
Dec 10, 2018
Results first posted
Jan 6, 2021
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03025542
Lead sponsor
UCB Biopharma SRL
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 19, 2017
Start date
Dec 27, 2016
Primary completion
Dec 11, 2017
Completion
Dec 11, 2017
Results posted
Jan 6, 2021
Last update
Mar 24, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273(UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion